Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report

Hormonal chemotherapy in combination with cytokines was applied to a 45-year-old woman with mammary cancer complicated with systemic diffused bone metastasis. The patient received CAF therapy using Cyclo-Phosphamide (CPM), 5-fluorouracil (5-FU), and Pirarubicin (THP) as chemotherapy and Medroxyprogestrone (MPA) as hormonal therapy. In addition to these therapies, natural human interferon-α (nHuIFN-α) and natural human tumor necrosis factor-α (nHuTNF-α) were also administered. CPM (50 mg/day), 5-FU (100 mg/day), and MPA (60 mg/day) were orally administered consecutively. One shot of THP (20 mg) was intravenously administered ad libitum under monitoring the white blood cell number. At first, nHuIFN-α and nHuTNF-α were infused in a small amount and maintained the levels of 2 x 10⁶ IU/day and 2,860 JRU/day, respectively. CA15-3, a tumor marker, gradually decreased soon after these treatments. Six months later, it decreased from 348.0 u/ml of pretreatments to 48 u/ml which is within normal value. In parallel with this decrease, metastatic tumors in the anterior chest and right axillae became markedly smaller, each slowing PR and CR, respectively. Eight months after the onset of the treatments, the tumor marker still maintained low level and general conditions of the patient was fairly improved. The prognosis of patients with breast cancer accompanied by systemic diffused bone metastasis is usually in a critical condition. In this case, however, hormonal chemotherapy combined with cytokines was effective on this kind of malignant cancer.